Document is current
Any future updates will be listed below
-
Authors
Dal Santo, Francesco https://orcid.org/0000-0002-9879-6443
García-Portilla, María Paz https://orcid.org/0000-0003-3643-1622
Fernández-Egea, Emilio https://orcid.org/0000-0003-4128-8955
González-Blanco, Leticia https://orcid.org/0000-0001-6238-4773
Sáiz, Pilar A. https://orcid.org/0000-0002-5705-4523
Giordano, Giulia Maria
Galderisi, Silvana https://orcid.org/0000-0002-1592-7656
Bobes, Julio https://orcid.org/0000-0003-2187-4033
- License Information
-
More Information
Article History
Received: 29 June 2024
Accepted: 16 August 2024
First Online: 30 September 2024
Competing interests
: F.D.S. has received grants from the Spanish Foundation of Psychiatry and Mental Health and the European Psychiatric Association. MPGP has been a consultant to and/or has received honoraria/grants from Angelini, Alianza Otsuka-Lundbeck, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, and Pfizer. EFE has received consultancy honoraria from Boehringer-Ingelheim (2022), Atheneum (2022) and Rovi (2022), speaker fees by Adamed (2022) and Otsuka (2023) and training and research material from Merz (2020). L.G.B. has been a consultant to and/or has received honoraria/grants from the Spanish Foundation of Psychiatry and Mental Health, European Psychiatric Association, Otsuka, Lundbeck, Janssen-Cilag and Pfizer. P.A.S. has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Commission, GlaxoSmithKline, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional sobre Drogas and Servier. S.G. has been a consultant to Angelini, Gedeon Richter-Recordati, Innova Pharma-Recordati Group within the last 2 years and has received honoraria/grants from Angelini, Gedeon Richter-Recordati, Janssen Pharmaceuticals, Janssen Cilag, Lundbeck and Recordati Pharmaceuticals. J.B. has received research grants and served as consultant, advisor or speaker within the last 5 years for: AB-Biotics, Acadia Pharmaceuticals, Angelini, Casen Recordati, D&A Pharma, Exeltis, Gilead, GSK, Ferrer, Indivior, Janssen-Cilag, Lundbeck, Mundipharma, Otsuka, Pfizer, Reckitt-Benckiser, Roche, Sage Therapeutics, Servier, Shire, Schwabe Farma Ibérica, research funding from the Spanish Ministry of Economy and Competiveness - Centro de Investigación Biomedica en Red area de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III-, Spanish Ministry of Health, Social Services and Equality -Plan Nacional sobre Drogas- and the 7th Framework Programme of the European Union. All other authors declare that they have no conflicts of interest.
